Entrectinib jako jediný prostředek v počáteční terapii pro děti
FÁZE 2 Studie entrektinibu jako samostatného činidla v počáteční terapii pro děti
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE
- To determine the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) (Cohort 1).
SECONDARY OBJECTIVES
- To estimate the 2-year and 5-year progression free survival (PFS) and overall survival (OS) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
- To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
- To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused HGG treated who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 1).
- To describe the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG (Cohort 2).
- To estimate the 2-year and 5-year PFS and OS in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
- To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
- To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 2).
- To describe toxicities experienced by patients younger than 3 years of age treated with entrectinib (Cohort 1 and 2).
- To evaluate number of patients that are screened for the study and eligible versus enrolled and treated with entrectinib (Cohort 1 and 2).
- To measure the time intervals (days) from time of initial diagnostic surgery to screening and enrollment in this study (Cohort 1 and 2).
The trial will have 2 cohorts: Cohort 1: patients diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) and Cohort 2: patients diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG.
Patients receive entrectinib enterally once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients requiring bridging therapy prior to starting entrectinib may receive cyclophosphamide intravenously (IV) over 1 hour on day 1, etoposide IV over 1 hour on day 1 and 2, carboplatin IV over 1 hour on day 2, filgrastim subcutaneously (SC) or IV or pegfilgrastim SC on day 3.
A gross total resection or significant debulking may become possible if a response to entrectinib is seen. If surgical resection is performed and a gross total resection is achieved, 24 cycles of entrectinib will be completed, including those before and after surgery.
After treatment, patients will be followed for 5 years.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Tabatha E. Doyle, RN
- Telefonní číslo: 901-595-2544
- E-mail: tabatha.doyle@stjude.org
Studijní záloha kontaktů
- Jméno: Daniel Moreira, MD, MEd
- Telefonní číslo: 901-585-1911
- E-mail: daniel.moreira@stjude.org
Studijní místa
-
-
-
São Paulo, Brazílie, 08270-070
- Nábor
- Hospital Santa Marcelina
-
Vrchní vyšetřovatel:
- Sidnei Epelman, MD
-
Kontakt:
- Sidnei Epelman, MD
- Telefonní číslo: +55 11 2522-2472
- E-mail: epelman@inctrbrasil.org
-
São Paulo, Brazílie, 04039-001
- Nábor
- GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
-
Kontakt:
- Andrea M. Cappellano, MD
- Telefonní číslo: +55 11 5080-8400
- E-mail: andreacappellano@graacc.org.br
-
Vrchní vyšetřovatel:
- Andrea M. Cappellano, MD
-
-
São Paulo
-
Barretos, São Paulo, Brazílie, 14784400
- Nábor
- Hospital de Câncer de Barretos
-
Kontakt:
- Thais J. Vampre, MD
- Telefonní číslo: 17 3321-6647
- E-mail: thaisjunq79@gmail.com
-
Vrchní vyšetřovatel:
- Thais J. Vampre, MD
-
-
-
-
-
Amman, Jordán, 11941
- Nábor
- King Hussein Cancer Center
-
Kontakt:
- Nisreen Amayiri, MD
- Telefonní číslo: 6376 (962 6) 5300460
- E-mail: namayiri@khcc.jo
-
Vrchní vyšetřovatel:
- Nisreen Amayiri, MD
-
-
-
-
-
Lima, Peru
- Nábor
- Instituto Nacional de Enfermedades Neoplásicas
-
Kontakt:
- Rosdali Coronado, MD
- Telefonní číslo: +51 991765893
- E-mail: rosdali.diaz.c@upch.pe
-
Vrchní vyšetřovatel:
- Rosdali Coronado, MD
-
-
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38105
- Nábor
- St. Jude Children's Research Hospital
-
Kontakt:
- Tabatha E. Doyle, RN
- Telefonní číslo: 901-595-2544
- E-mail: tabatha.doyle@stjude.org
-
Vrchní vyšetřovatel:
- Daniel Moreira, MD, MEd
-
Kontakt:
- E-mail: GLOBOTRK@stjude.com
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria: Screening Phase
- Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
- Participant with presumed newly diagnosed tumor in the supratentorial compartment
- Patient must have measurable disease based on RAPNO criteria
- ≤84 days since surgery (resection or biopsy)
- Available tumor tissue for central review
- Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines
Exclusion Criteria: Screening Phase
- Previous exposure to cytotoxic chemotherapy or radiotherapy
Inclusion Criteria: COHORT 1
-
Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)
-
High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review
-
Patients must have measurable disease as defined by RAPNO criteria
-
Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation
-
≤28 days since study screening
-
Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks
-
Neurologic deficits must have been stable for at least 7 days prior to study enrollment
-
Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)
-
Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)
-
Absolute neutrophil count >1,000/µL
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)
-
Bilirubin ≤ 1.5 x ULN
-
Adequate renal function as defined by the following age-based serum creatinine concentrations:
- 0 to <1 year: 0.5 mg/dL
- 1 to <2 years: 0.6 mg/dL
- 2 to 3 years: 0.8 mg/dL
-
Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%
-
Screening and enrollment consents signed
-
Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures
Inclusion Criteria: COHORT 2
-
Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)
-
CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review
-
Patients must have measurable disease as defined by RAPNO criteria
-
Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation
-
≤28 days since study screening
-
Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks
-
Neurologic deficits must have been stable for at least 7 days prior to study enrollment.
-
Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)
-
Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);
-
Absolute neutrophil count >1,000/µL.
-
ALT and ALT ≤2.5x the upper limit of normal (ULN)
-
Bilirubin ≤ 1.5 x ULN
-
Adequate renal function as defined by the following age-based serum creatinine concentrations:
- 0 to <1 year: 0.5 mg/dL
- 1 to <2 years: 0.6 mg/dL
- 2 to 3 years: 0.8 mg/dL
-
Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%
-
Screening and enrollment consents signed
-
Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures
Exclusion Criteria: COHORT 1 AND 2
- Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
- History of recent (3 months) symptomatic congestive heart failure
- Known active, uncontrolled infection (bacterial, fungal, or viral)
- Receiving enzyme inducing antiepileptic drugs (EIAEDs)
- Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation
- Receiving another investigational agent concurrently
- Surgery within 2 weeks prior to treatment enrollment
- Patients with known hypersensitivity to excipients of the investigational medicinal product
- Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption
- Inability to take medication enterally
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Entrectinib therapy, Cohort 1 and Cohort 2
Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description. Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given orally (PO) or enterally
Ostatní jména:
Given intravenous (IV)
Ostatní jména:
Given subcutaneous (SQ) or IV
Ostatní jména:
Given SQ as part of recommended Bridging Therapy instead of G-CSF.
Ostatní jména:
A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall response rate (ORR) (Cohort 1)
Časové okno: After cycle 4 (each cycle is 28 days).
|
ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations. |
After cycle 4 (each cycle is 28 days).
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression free survival (PFS) (Cohort 1)
Časové okno: At 2 and 5 years
|
PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method. |
At 2 and 5 years
|
|
Overall survival (OS) (Cohort 1)
Časové okno: At 2 and 5 years
|
OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method. |
At 2 and 5 years
|
|
Duration of response (DOR) (Cohort 1)
Časové okno: Up to 5 years
|
DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time. |
Up to 5 years
|
|
Patients who have second surgeries (Cohort 1)
Časové okno: Up to 5 years
|
Percentage of patients who had second surgeries. |
Up to 5 years
|
|
Patients who undergo gross-total resection after treatment (Cohort 1)
Časové okno: Up to 5 years
|
Percentage of patients who underwent a gross-total resection. |
Up to 5 years
|
|
ORR (Cohort 2)
Časové okno: After cycle 4 (each cycle is 28 days).
|
ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations. |
After cycle 4 (each cycle is 28 days).
|
|
PFS (Cohort 2)
Časové okno: At 2 and 5 years
|
PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method. |
At 2 and 5 years
|
|
OS (Cohort 2)
Časové okno: At 2 and 5 years
|
OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method. |
At 2 and 5 years
|
|
DOR (Cohort 2)
Časové okno: Up to 5 years
|
DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time. |
Up to 5 years
|
|
Patients who have second surgeries (Cohort 2)
Časové okno: Up to 5 years
|
Percentage of patients who had second surgeries. [Time Frame: Up to 5 years] |
Up to 5 years
|
|
Patients who undergo gross-total resection after treatment (Cohort 2)
Časové okno: Up to 5 years
|
Percentage of patients who underwent a gross-total resection. |
Up to 5 years
|
|
Incidence of adverse events (Cohort 1 and 2)
Časové okno: Up to 5 years
|
Percentage of adverse events on therapy including Entrectinib, captured using National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. |
Up to 5 years
|
|
Number of patients screened versus enrolled and treated (Cohort 1 and 2)
Časové okno: Up to 5 years
|
Number of enrolled and treated patients as a percentage of number of patients screened and eligible for study. |
Up to 5 years
|
|
Time from initial diagnostic surgery to screening and enrollment (Cohort 1 and 2)
Časové okno: Up to 5 years
|
Median time in days from initial surgery to screening and enrollment on study. |
Up to 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Daniel Moreira, MD, MEd, St. Jude Children's Research Hospital
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci nervového systému
- Novotvary podle místa
- Novotvary
- Novotvary podle histologického typu
- Novotvary, žlázové a epiteliální
- Novotvary, neuroepiteliální
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Novotvary nervového systému
- Gliom
- Novotvary centrálního nervového systému
- Peptidy
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Organické chemikálie
- Uhlovodíky
- Uhlovodíky, cyklické
- Biologické faktory
- Uhlohydráty
- Podophyllotoxin
- Tetrahydronaftalenes
- Naftalenes
- Polycyklické aromatické uhlovodíky
- Uhlovodíky, aromatické
- Polycyklické sloučeniny
- Glukosidy
- Glykosidy
- Koordinační komplexy
- Fosforamidové hořčice
- Sloučeniny hořčice dusíku
- Hořčičné sloučeniny
- Uhlovodíky, halogenované
- Fosforamidy
- Organofosforové sloučeniny
- Mezibuněčné signalizační peptidy a proteiny
- Glykoproteiny
- Glykokonjugáty
- Faktory stimulující kolonie
- Růstové faktory hematopoetických buněk
- Cytokiny
- Cyklofosfamid
- Etoposid
- Karboplatina
- Chirurgické postupy, operativní
- Faktor stimulující kolonie granulocytů
- Filgrastim
- Entrectinib
- Pegfilgrastim
Další identifikační čísla studie
Další identifikační čísla studie
- GLOBOTRK
- NCI-2024-02977 (Identifikátor registru: NCI Clinical Trial Registration Program)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
Časový rámec sdílení IPD
Data will be made available at the time of article publication.
Kritéria přístupu pro sdílení IPD
Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .